ClinicalTrials.gg
RecruitingNCT03401762Updated Apr 8, 2026

Wearable MCI to Reduce Muscle Co-activation in Acute and Chronic Stroke

An interventional study of MCI and Sham MCI in Stroke and Stroke, Acute, sponsored by Northwestern University. Recruiting at 1 site in United States. Open to participants aged 21 Years and older. Per ClinicalTrials.gov, last updated 2026-04-08.

Sponsored by Northwestern University · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Started Jan 2018; still recruiting 8 years 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
96
Allocation
Randomized
Ages
21 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 24 studies in Stroke by Northwestern University — 6 open to participants now, 8 under way, none of them phase 3. Stroke · Northwestern University.

Planned enrollment
2nd of 20
96 · median 52
Started
2018
with 1 other
No phase
17 of 24
5 open now
Registered
10th of 24
by date

Among the 24 studies in Stroke by Northwestern University, this one is the 2nd largest by planned enrollment of the 20 interventional ones that give a count, is one of 2 that started in 2018, is one of 17 with no phase, and was the 10th registered.

Stroke

8,269 studies on the registry are indexed under Stroke; 2,062 are open to participants now.

Browse Stroke studies →

Open to participants now

6 of the 24 studies in Stroke by Northwestern University are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 6 open studies →

Where they have run

Who these studies take

Of the 1,419 Stroke studies recruiting now, 695 (49%) set no upper age limit and 283 (20%) stop at 75 or younger; 77 take children under 18; 197 take healthy volunteers.

This study: 21 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 24 studies in Stroke by Northwestern University, or all of them as a file.
02

Study summary

The purpose of the study is to explore the feasibility of using a wearable device, called a myoelectric-computer interface (MCI), to improve arm movement in people who have had a stroke.

Impaired arm movement after stroke is caused not just by weakness, but also by impaired coordination between joints due to abnormal co-activation of muscles. These abnormal co-activation patterns are thought to be due to abnormal movement planning.The MCI aims to reduce abnormal co-activation by providing feedback about individual muscle activations.

This randomized, controlled, blinded study will test the home use of an MCI in chronic and acute stroke survivors.

03

Conditions studied

  • Stroke
  • Stroke, Acute

Browse trials for

Keywords

  • rehabilitation
04

Who can participate

Ages eligible
21 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Chronic stroke participants

  • Hemiparesis from first ever stroke at least 6 months prior to screening
  • Severe motor impairment (FMA of 7-30)
  • At least some voluntary shoulder and elbow muscle activation.

Acute stroke participants

  • Hemiparesis from first ever stroke within the past 21 days
  • Severe motor impairment (FMA of 3-20), or total Manual Motor Score of 1-8 combined in Shoulder Abduction and Finger Extensors

Exclusion criteria

Exclusion Criteria:

  • Cognitive impairment with at least moderately impaired attention, or unable to follow instructions of the MCI task
  • Visual impairment (such as hemianopia) preventing full view of the screen
  • Anesthesia or neglect in the affected arm, or visual hemineglect (score of 2 on the NIH Stroke Scale Extinction and Inattention subtest).
  • Participation in another study on the affected arm within 6 weeks of enrollment or any pharmacological study
  • Inability to understand or follow commands in English due to aphasia or other reason
  • Diffuse or multifocal infarcts
  • Substantial arm pain preventing participation for 90 minutes a day
  • New spasticity treatment (pharmacological or Botox)
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
96 participants (estimated)

Study arms

  • Experimental
    Chronic stroke MCI Electromyogram (EMG) pairs

    Decoupling 2 muscles at a time with MCI

    Behavioral: MCI

  • Experimental
    Chronic stroke MCI EMG triplets

    Decoupling 3 muscles at a time with MCI

    Behavioral: MCI

  • Experimental
    Chronic stroke MCI while reaching

    Decoupling muscles with MCI while reaching to targets

    Behavioral: MCI

  • Sham comparator
    Chronic stroke Sham MCI

    Sham control group

    Behavioral: Sham MCI

  • Experimental
    Acute stroke MCI

    Decoupling muscles with MCI in acute stroke subjects

    Behavioral: MCI

  • Sham comparator
    Acute stroke Sham MCI

    Acute stroke subjects sham comparator

    Behavioral: Sham MCI

Interventions

  • BehavioralMCI

    EMG-controlled game

  • BehavioralSham MCI

    Sham control game

06

What researchers measure

Primary outcomes

  1. Wolf Motor Function Test

    Timed

    Time frame: baseline to 6 weeks

Secondary outcomes

  1. Fugl-Meyer Assessment - Upper Extremity (UE)

    Time frame: baseline to 6 weeks

  2. Motor Activity Log

    Time frame: baseline to 6 weeks

  3. Modified Ashworth Scale

    Total score

    Time frame: baseline to 6 weeks

  4. Fugl-Meyer Assessment UE

    Time frame: baseline to 10 weeks

  5. Wolf Motor Function Test

    Timed

    Time frame: baseline to 10 weeks

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Khorasani A, Gorski CM, Hung NT, Hulsizer J, Paul V, Tomic G, Prakash PR, Park S, Seo G, Houskamp EJ, Lanis J, Hunzeker M, King E, Chappel A, Jampol A, Patel P, Gallagher C, Galant R, Rucker G, Lee J, Harvey RL, Roh J, Slutzky MW. Wearable Myoelectric Interface for Neurorehabilitation (MINT) to Recover Arm Activity After Stroke: A Randomized Controlled Trial. Neurorehabil Neural Repair. 2026 Jun 8:15459683261454937. doi: 10.1177/15459683261454937. Online ahead of print. PubMed 42261097 ↗
  • Khorasani A, Gorski CM, Hung NT, Hulsizer J, Paul V, Tomic G, Prakash PR, Park S, Seo G, Houskamp EJ, Lanis J, Hunzeker M, King E, Chappel A, Jampol A, Patel P, Gallagher C, Galant R, Rucker G, Lee J, Harvey R, Roh J, Slutzky MW. Wearable Myoelectric Interface for Neurorehabilitation (MINT) to Recover Arm Function: a Randomized Controlled Trial. medRxiv [Preprint]. 2025 Jun 25:2025.06.24.25330240. doi: 10.1101/2025.06.24.25330240. PubMed 40666333 ↗
  • Khorasani A, Hulsizer J, Paul V, Gorski C, Dhaher YY, Slutzky MW. Myoelectric interface for neurorehabilitation conditioning to reduce abnormal leg co-activation after stroke: a pilot study. J Neuroeng Rehabil. 2024 Jan 20;21(1):11. doi: 10.1186/s12984-024-01305-0. PubMed 38245730 ↗
  • Khorasani A, Hulsizer J, Paul V, Gorski C, Dhaher YY, Slutzky MW. Myoelectric interface for neurorehabilitation conditioning to reduce abnormal leg co-activation after stroke: a pilot study. Res Sq [Preprint]. 2023 Oct 9:rs.3.rs-3398815. doi: 10.21203/rs.3.rs-3398815/v1. PubMed 37886579 ↗
  • Hung NT, Paul V, Prakash P, Kovach T, Tacy G, Tomic G, Park S, Jacobson T, Jampol A, Patel P, Chappel A, King E, Slutzky MW. Wearable myoelectric interface enables high-dose, home-based training in severely impaired chronic stroke survivors. Ann Clin Transl Neurol. 2021 Sep;8(9):1895-1905. doi: 10.1002/acn3.51442. Epub 2021 Aug 20. PubMed 34415114 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2018 (actual). Primary completion is estimated for Apr 2027, 111 months after the start.

Of 3,119 non-industry interventional studies with no phase under Stroke, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 46. This study's planned 111 months is above that.

Counting every sponsor, half of 3,263 studies reached it within 23 months; a quarter within 10 and three quarters within 46.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 9, 2018
First posted
Jan 17, 2018
StartActual
Jan 15, 2018
Primary completionEst.
Apr 2027
CompletionEst.
Apr 2027
Last update
Apr 8, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 8, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03401762
Responsible party
Marc Slutzky (Associate Professor, Northwestern University) — Principal investigator
First posted
Jan 17, 2018
Start date
Jan 15, 2018
Primary completion
Apr 2027 (estimated)
Completion
Apr 2027 (estimated)
Last update
Apr 8, 2026

Study contacts

Marc W Slutzky, MD, PhD
Contact
mslutzky@northwestern.edu
3125034653
Cynthia Gorski
Contact
cynthia.gorski@northwestern.edu

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion